

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human TNF- α in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant canine TNF- α , recombinant bovine TNF- α , recombinant rat TNF- α , recombinant equine TNF- α , and recombinant cotton rat TNF- α is observed.
Source	Polyclonal Goat IgG
Purification	Protein A or G purified
Immunogen	<i>E. coli</i> -derived recombinant human TNF- α Val77-Leu233 Accession # P01375
Endotoxin Level	<0.10 EU per 1 μ g of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	1 μ g/mL	Recombinant Human TNF- α (Catalog # 210-TA)
Neutralization		Measured by its ability to neutralize TNF- α -induced cytotoxicity in the L-929 mouse fibroblast cell line [Matthews, N. and M.L. Neale (1987) in <i>Lymphokines and Interferons, A Practical Approach</i> . Clemens, M.J. <i>et al.</i> (eds): IRL Press. 221]. The Neutralization Dose (ND ₅₀) is typically 0.05-0.25 μ g/mL in the presence of 0.25 ng/mL Recombinant Human TNF- α and 1 μ g/mL actinomycin D.

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 1 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Tumor necrosis factor alpha (TNF- α), also known as cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, apoptosis, and immune system development. TNF- α is produced by a wide variety of immune and epithelial cell types (1, 2). Human TNF- α consists of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD) (3). Within the ECD, human TNF- α shares 97% aa sequence identity with rhesus and 71%-92% with bovine, canine, cotton rat, equine, feline, mouse, porcine, and rat TNF- α . The 26 kDa type 2 transmembrane protein is assembled intracellularly to form a noncovalently linked homotrimer (4). Ligation of this complex induces reverse signaling that promotes lymphocyte costimulation but diminishes monocyte responsiveness (5). Cleavage of membrane bound TNF- α by TACE/ADAM17 releases a 55 kDa soluble trimeric form of TNF- α (6, 7). TNF- α trimers bind the ubiquitous TNF RI and the hematopoietic cell-restricted TNF RII, both of which are also expressed as homotrimers (1, 8). TNF- α regulates lymphoid tissue development through control of apoptosis (2). It also promotes inflammatory responses by inducing the activation of vascular endothelial cells and macrophages (2). TNF- α is a key cytokine in the development of several inflammatory disorders (9). It contributes to the development of type 2 diabetes through its effects on insulin resistance and fatty acid metabolism (10, 11).

References:

1. Idriss, H.T. and J.H. Naismith (2000) *Microsc. Res. Tech.* **50**:184.
2. Hehlgans, T. and K. Pfeffer (2005) *Immunology* **115**:1.
3. Pennica, D. *et al.* (1984) *Nature* **312**:724.
4. Tang, P. *et al.* (1996) *Biochemistry* **35**:8216.
5. Eissner G. *et al.* (2004) *Cytokine Growth Factor Rev.* **15**:353.
6. Black, R.A. *et al.* (1997) *Nature* **385**:729.
7. Moss, M.L. *et al.* (1997) *Nature* **385**:733.
8. Loetscher, H. *et al.* (1991) *J. Biol. Chem.* **266**:18324.
9. Clark, I.A. (2007) *Cytokine Growth Factor Rev.* **18**:335.
10. Romanatto, T. *et al.* (2007) *Peptides* **28**:1050.
11. Hector, J. *et al.* (2007) *Horm. Metab. Res.* **39**:250.